South Korea
· Delayed Price · Currency is KRW Pharmicell Company Description
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally.
The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty.
The company’s products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; Hearticellgram_AMI, a cardiac disease drug; Cellgram_CKD for the treatment of chronic kidney disease; and Cellgram_AKI for the treatment of acute kidney disease.
It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, as well as clinical development and commercialization services for new drugs.
Further, it operates Twelve, a stem cell bank; and develops and sells stem cell culture media cosmetics.
The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011.
Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 1968 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Hyun-Soo Kim |
Contact Details
Address: Ssangbong Building Seoul South Korea | |
| Phone | 82 2 3496 0114 |
| Website | pharmicell.com |
Stock Details
| Ticker Symbol | 005690 |
| Exchange | Korea Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7005690003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Hyun-Soo Kim | Chief Executive Officer and Inside Director |